The Sevillian technology company iGluco has obtained a loan of nearly 250,000 euros from the CDTI’s Cervera transfer program to validate its smart, needle-free glucose measurement device that improves the quality of life of diabetics. iGluco has obtained this grant with the support and advice of CTA (Technological Corporation of Andalusia).

“Thanks to CTA, we have obtained the approval of our project IGLUCO – NON INVASIVE GLUCOSE MEASUREMENT SYSTEM in the CDTI within its R+D Cervera Transfer program”, says the CEO and founder of iGluco, Pedro Luis Navarro Gómez, who adds that “we value the service provided by CTA to place at our disposal a team capable of perfectly matching the economic and technical scope of our work in this project”.

CDTI’s Cervera Transfer R&D projects, such as the one granted to iGluco, finance individual R&D projects developed by companies that collaborate with state-level Technology Centers in Cervera priority technologies.

iGluco, together with the Biomedical Engineering Group of the University of Seville (US), intends to bring the results of its research to the market, thanks to which it has developed an intelligent device that can measure blood glucose concentration (glycemia) on the spot by means of an optoelectric system. The reading is done through the index finger via infrared and, once done, is sent to the smartphone, allowing for intelligent and accurate tracking.

The support provided by CTA to iGluco is part of its support service for raising external financing for technology-based entrepreneurs, with which it has a success rate of over 45% in the Neotec program of the CDTI (@CDTIoficial) and over 94% in ENISA, among other programs.